The Patron-in-Chief of the conference will be SU acting Vice-Chancellor Prof. Dr. Khalil-ur-Rehman Khoumbati, while the ...

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its recently published findings from its "Targeted Intra-tumoral Hyperthermia with Uniquely ...

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its ...

Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®▼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, ...

As we approach another year of groundbreaking research in cancer care and significant treatment innovations, various companies are taking the ...